Dr. Sokol clarified that "this composite drug is a broad-spectrum antibiotic; accordingly, some compounds can affect not only bacteria but also yeasts and other fungal pathogens." This information was reported by "Russia Today" news network, citing the local "Izvestia" newspaper.

The innovative medication assists in the treatment of Staphylococcus aureus, various types of poisoning, aspergillosis, candidiasis, and other diseases.

Meanwhile, Dr. Yelena Nikolskaya, a senior researcher at the institute, reported that "preliminary tests have demonstrated the effectiveness and safety of the innovative drug. The next phase is to test it on animals; that is to conduct a complete cycle of preclinical tests (on animals), which takes about three years. If we obtain positive results, we can then move on to clinical trials on humans."